Navigation Links
Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
Date:4/1/2008

EMERYVILLE, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced that, effective April 1, 2008, Matthew M. Loar has been appointed Chief Financial Officer. Mr. Loar will be based at the Company's headquarters in Emeryville. Mr. Loar joins the company from Osteologix, where he has served as Chief Financial Officer since 2006.

"Matt has a proven track record as a chief financial officer, and we will look to his expertise to help guide our financial and business strategy," said Paul E. Freiman, President and Chief Executive Officer of Neurobiological Technologies. "His wealth of experience in helping to run several businesses combined with his knowledge of industry accounting requirements, SEC compliance and the biotech investment community will be real assets as our team continues to advance our strategic vision."

Mr. Loar is a Certified Public Accountant and has over twenty years experience in finance and accounting. Mr. Loar has a strong track record working with growing pharmaceutical and biotechnology companies, and has played a key role in several major corporate collaborations, successfully completing public and private equity financings and implementing the provisions of Sarbanes-Oxley Act at a public biotechnology company.

"NTI has a strong management team, a unique product development strategy, and tremendous potential for their phase 3 investigational drug, Viprinex(TM).

I look forward to becoming a key contributor to their future growth," said Mr. Loar. "NTI's efforts to develop new and improved central nervous system therapeutics are indeed exciting, and I'm anxious to start working with the other members of NTI's team to maximize the organization's overall potential."

Since the fall of 2006, Mr. Loar held the position of Chief Financial Officer at Osteologix, Inc. Prior to his tenure at Osteologix, he spent eleven years with Genelabs Technologies, Inc. where he held several positions, including Chief Financial Officer, Vice President of Finance and Controller. Earlier in his career, from 1991 through 1995, Mr. Loar was Corporate Accounting Manager for an international manufacturing company with approximately $500 million in annual product sales. From 1986 to 1991 he was audit manager with Coopers & Lybrand, a predecessor firm to PriceWaterhouseCoopers. Mr. Loar graduated from the University of California, Berkeley and is a member of the American Institute of CPAs. He is a member of Financial Executives International and for two years served as treasurer of their Silicon Valley Chapter.

As an inducement to his entering into employment with the Company, Mr. Loar was awarded an option in accordance with NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) to purchase up to 150,000 shares of the Company's common stock outside of the Company's stockholder-approved equity incentive plans, at an exercise price per share equal to the fair market value of the Company's common stock on April 1, 2008. The inducement option, which will have a term of 10 years, will vest with respect to one-eighth of the underlying shares six months after the date of grant and then with respect to the remaining shares ratably over the next 42 months.

About Neurobiological Technologies

Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate in phase 3 clinical testing is Viprinex(TM) (ancrod), a novel agent with multiple mechanisms that is specifically designed to expand the treatment window for treating acute ischemic stroke, one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. Its pipeline includes other drug candidates in early-stage development, including a first-of-its-kind drug for the treatment of Alzheimer's disease.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
2. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
3. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
4. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. Neurobiological Technologies Sets Date for Second Quarter Financial Results
8. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
10. Neurobiological Technologies Sets Date for Research and Development Day
11. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... for clean technology companies in the TSX Venture 50 TM ... listed on the TSX Venture Exchange, in each of five ... technology & life sciences, diversified industries and technology – ... return on investment, market cap growth, trading volume and analyst ...
(Date:2/8/2016)... Feb. 8, 2016  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has ... with Hercules Technology Growth Capital, Inc. and Hercules ... in financing. --> ... million of financing under the loan and security ...
(Date:2/8/2016)... , Feb. 8, 2016 Novan, Inc. today announced that ... the Board of Directors of Novan. In addition, Robert Keegan ... North Carolina . --> ... announced that it received a total of $32.8 million of net ... its private investor network originating throughout the Research Triangle area of ...
(Date:2/8/2016)... , Feb. 8, 2016  BioElectronics Corporation (OTC ... devices, announced today that it is responding to ... from the Securities and Exchange Commission posted on ... , Chairman of the Board of BioElectronics Corporation ... Business Administration at The Fuqua School of Business, ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016  BioMEMS devices deployed in ... on medical screening and diagnostic applications, such ... devices that facilitate and assure continuous monitoring ... are being bolstered through new opportunities offered ... acquisition coupled with wireless connectivity and low ...
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):